SCHEMBL29525618

SCHEMBL29525618

CC(C)C[C@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1c[nH]cn1)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
REN P00797 3/20 0.58
OPRM1 P35372 2/20 0.55
OPRD1 P41143 2/20 0.55
OPRK1 P41145 2/20 0.55
SLC6A2 P23975 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6516908 1.00 REN (0.58) RENOPRM1OPRD1OPRK1SLC6A2
SCHEMBL30480493 0.92 OPRM1 (0.55) RENOPRM1OPRD1OPRK1SLC6A2
SCHEMBL30480492 0.92 OPRM1 (0.55) RENOPRM1OPRD1OPRK1SLC6A2
SCHEMBL30454361 0.92 REN (0.51) RENOPRM1OPRD1OPRK1SLC6A2
SCHEMBL31072130 0.91 REN (0.46) RENOPRM1
SCHEMBL29649768 0.91 OPRM1 (0.54) RENOPRM1OPRD1OPRK1SLC6A2
SCHEMBL31108671 0.91 REN (0.55) RENOPRM1OPRD1OPRK1SLC6A2
SCHEMBL31206334 0.90 APLNR (0.59) RENOPRM1OPRD1OPRK1
SCHEMBL29448209 0.90 REN (0.66) REN
SCHEMBL11092435 0.90 REN (0.47) RENSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042811-A1 NOVEL PEPTIDE HORMONE ANALOGUES IP2IPO INNOVATIONS LTD (GB) 2026-02-12 US disclosed
US-12516095-B2 Peptide hormone analogues IP2IPO INNOVATIONS LIMITED (GB) 2026-01-06 US disclosed
US-12497438-B2 Compounds IP2IPO INNOVATIONS LIMITED (GB) 2025-12-16 US disclosed
US-20250368710-A1 NOVEL COMPOUNDS IP2IPO INNOVATIONS LTD (GB) 2025-12-04 US disclosed
EP-4622672-A1 AMYLIN ANALOGUES IP2IPO Innovations Limited (GB) 2025-10-01 EP disclosed
CN-114450300-B Novel compounds IP2IPO创新有限公司 2025-05-20 CN disclosed
EP-3720873-B1 GLUCAGON-LIKE PEPTIDES IP2IPO INNOVATIONS LTD (GB) 2024-12-04 EP disclosed
US-20240336669-A1 NOVEL COMPOUNDS IP2IPO INNOVATIONS LIMITED (GB) 2024-10-10 US disclosed
WO-2024175930-A1 COMPOUNDS IP2IPO INNOVATIONS LIMITED (GB) 2024-08-29 WO disclosed
WO-2024110763-A1 AMYLIN ANALOGUES IP2IPO INNOVATIONS LIMITED (GB) 2024-05-30 WO disclosed
EP-4259646-A1 NOVEL COMPOUNDS IP2IPO Innovations Limited (GB) 2023-10-18 EP disclosed
US-11591380-B2 Glucagon-like peptides IP2IPO INNOVATIONS LIMITED (GB) 2023-02-28 US disclosed
US-20220315636-A1 NOVEL PEPTIDE HORMONE ANALOGUES IP2IPO INNOVATIONS LIMITED (GB) 2022-10-06 US disclosed
WO-2022123271-A1 NOVEL COMPOUNDS IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2022-06-16 WO disclosed
CN-114450300-A Novel compounds IP2IPO创新有限公司 2022-05-06 CN disclosed
EP-3983065-A1 NOVEL PEPTIDE HORMONE ANALOGUES IP2IPO Innovations Limited (GB) 2022-04-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240336669-A1 NOVEL COMPOUNDS GLP1R, GIPR, GPR119 REN 487/4885OPRM1 1499/4885OPRD1 935/4885
US-12497438-B2 Compounds GLP1R, GPR119, GIPR REN 619/4885OPRM1 1290/4885OPRD1 1165/4885
US-20220315636-A1 NOVEL PEPTIDE HORMONE ANALOGUES GLP1R, GIPR, GPR119 REN 349/4885OPRM1 1500/4885OPRD1 839/4885
US-20260042811-A1 NOVEL PEPTIDE HORMONE ANALOGUES GLP1R, GPR119, IAPP REN 215/4885OPRM1 883/4885OPRD1 605/4885
US-20250368710-A1 NOVEL COMPOUNDS GLP1R, GPR119, GIPR REN 939/4885OPRM1 1406/4885OPRD1 948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.